Serology and Molecular Diagnostics in Infectious Disease

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Serology detects host antibodies (IgM, IgG) indicating past or present exposure, but requires paired acute and convalescent samples (2-4 weeks apart) to confirm active infection by demonstrating a rising titre.
• Molecular diagnostics, such as PCR and RT-PCR, directly detect pathogen nucleic acid (DNA/RNA), offering high sensitivity and the ability to diagnose infection before seroconversion, but do not distinguish viable from non-viable organisms.
• The choice between serology and molecular testing hinges on the clinical question: serology for exposure history and surveillance, molecular diagnostics for confirming current infection, especially in acute disease, immunosuppressed animals, or neonates with maternal antibodies.
• Antimicrobial therapy can suppress or eliminate detectable pathogen nucleic acid in molecular tests, potentially leading to false negatives, while having minimal impact on pre-existing antibody levels detected by serology.
• Sample quality is paramount for diagnostic accuracy; molecular tests require proper transport media and cold chain to prevent nucleic acid degradation, while serology requires prompt serum separation to avoid hemolysis.
• Test interpretation necessitates consideration of population prevalence, vaccination history, maternal antibodies, stage of infection, and potential for cross-reactivity or assay inhibition, with validation for specific species and sample types being crucial.

Veterinary diagnostic microbiology has moved well beyond culture and biochemical identification. Serologic tests detect the host's humoral immune response to infection, while molecular assays detect the pathogen's nucleic acid directly. These two approaches answer different clinical questions, and choosing between them requires understanding what each test can and cannot establish. This article explains the principles, applications, and interpretive frameworks for serologic and molecular diagnostics across species, with emphasis on the decision logic a clinician applies when selecting and reading these tests.

The reader is assumed to be a veterinary student or practitioner who understands basic immunology and microbiology. The focus is on test principles and diagnostic reasoning, not on individual diseases or commercial kits. Where test performance data exist, they are presented with their sources. Where the evidence base is contested, that uncertainty is stated explicitly.

At a Glance

The Immunologic Basis of Serologic Testing

Serologic tests measure antibodies produced by the host in response to infection or vaccination. The kinetics of the antibody response follow a predictable pattern. IgM appears first, typically within days of antigen exposure, then declines over weeks. IgG appears later, peaks, and may persist for months to years. A single positive IgG titre therefore proves exposure at some point, but it does not distinguish recent infection from past infection or vaccination. Paired acute and convalescent samples taken two to four weeks apart are required to demonstrate a rising titre, which supports active or recent infection.

The choice of antibody class matters clinically. Detection of IgM suggests recent exposure, though cross-reactivity and persistence of IgM in some infections complicate interpretation. Detection of IgG alone is more useful for population surveillance and vaccination monitoring than for acute diagnosis. Some serologic formats detect total antibody without class distinction, which simplifies the assay but reduces interpretive power.

Serologic results must be interpreted in the context of vaccination history, maternal antibody in young animals, and the background prevalence of the agent in the population. A positive result in a low-prevalence population has a low positive predictive value, even with a highly specific test. This principle applies across species and is a central reason why serology is often used for screening and surveillance instead of for definitive diagnosis of individual acute cases.

The Molecular Basis of Nucleic Acid Detection

Molecular diagnostics detect pathogen-specific nucleic acid sequences. The polymerase chain reaction (PCR) amplifies a targeted DNA segment to detectable levels, and reverse transcription PCR (RT-PCR) converts RNA to cDNA before amplification, allowing detection of RNA viruses. Real-time PCR adds fluorescent detection during amplification, providing quantification and reducing the need for post-amplification handling.

The sensitivity of PCR is its principal advantage. It can detect very small numbers of organizms, which is valuable in chronic or low-burden infections. This sensitivity, however, creates a vulnerability to contamination. Amplicon carryover from previous runs, environmental nucleic acid, and improper sample handling can produce false positives. Laboratories must use physical separation of pre- and post-amplification areas, appropriate controls, and validated workflows to manage this risk.

PCR detects nucleic acid, not viable organizms. A positive result does not prove that the organizm is alive, replicating, or causing disease. This distinction matters after antimicrobial therapy, when dead organizms may remain detectable for days or weeks. It also matters in environmental or surveillance samples, where nucleic acid from nonviable organizms can persist. The clinician must therefore interpret a positive PCR result in light of the clinical presentation, the timing of sampling relative to therapy, and the known persistence characteriztics of the target organizm.

Test Performance and Quality Assurance

The clinical utility of any diagnostic test depends on its sensitivity, specificity, and predictive values in the population being tested. These parameters are not fixed properties of the test. They vary with disease prevalence, stage of infection, sample quality, and the reference standard used to validate the assay.

Commercial identification systems and susceptibility testing methods developed for human pathogens have been applied to veterinary isolates, but their accuracy varies widely depending on the bacterial species and the host animal from which the isolate was obtained. This observation, made in the context of veterinary diagnostic microbiology, extends to molecular and serologic assays as well. A test validated for one species or one sample type may perform differently in another.

Proficiency testing programs reveal substantial variation in laboratory performance. In one quality assurance program for laboratory animal diagnostics, major errors in antimicrobial susceptibility testing occurred in nearly 10 percent of test results, with considerable variation across bacterial groups and antimicrobial agents. This finding underscores that laboratory quality is not uniform, and clinicians should know the accreditation status and quality assurance practices of the laboratories they use.

Choosing Between Serology and Molecular Testing

The choice between serology and molecular testing follows from the clinical question. If the question is whether an animal has been exposed to an agent at any point, serology is appropriate. If the question is whether the agent is present in the animal at the time of sampling, molecular testing is appropriate.

Several scenarios favour molecular testing. Acute disease with a short clinical course often precedes seroconversion, so serology may be negative early in infection. Immunosuppressed animals may fail to mount a detectable antibody response. Neonates may have maternal antibody that confounds serologic interpretation. In these situations, direct detection of the pathogen is more informative.

Serology is preferred when the organizm is difficult or dangerous to culture, when infection is chronic and antibody levels are stable, or when population-level data are needed for surveillance and trade decisions. International standards for animal health surveillance and trade rely heavily on serologic testing, and the World Organization for Animal Health publishes the relevant standards for member countries.

Limitations and Failure Modes

Both test categories have characteriztic failure modes. Serology can produce false negatives in the window period before seroconversion, in immunocompromised hosts, and when antibody levels fall below the detection threshold. False positives arise from cross-reacting antibodies, prior vaccination, and nonspecific assay interference.

Molecular tests fail through inhibition of the polymerase enzyme by sample components, degradation of nucleic acid during transport, and contamination. Sample quality is the most controllable factor. Proper collection devices, transport media, and cold chain handling are essential, and these requirements differ from those of serologic sampling.

The evidence base for many veterinary diagnostic assays is limited. Validation studies are often small, reference standards vary, and comparative data across laboratories are scarce. Clinicians should treat published performance figures as estimates instead of fixed constants and should seek local or regional data where available.

Practical Test Selection: A Stepwise Approach

The decision to request serology, molecular testing, or both follows a logical sequence that begins with the clinical question. For a suspected infectious disease, the first decision point is whether the clinician needs to confirm active infection, document past exposure, or establish immune status. Active infection in a naive animal generally favours molecular detection of the pathogen itself. Past exposure or vaccination response requires serology. This distinction matters most in chronic or subclinical infections where antibody titres may persist long after the organizm has been cleared.

The second decision point is the stage of disease. In the first days of clinical signs, IgM serology may be negative while molecular tests can already detect nucleic acid. Conversely, after the organizm has been cleared from accessible sampling sites, serology may be the only positive test. Sampling site availability often dictates the choice. A pathogen that localizes to tissue not easily biopsied, such as the central nervous system, may be better approached with serology, whereas a respiratory pathogen shed in nasal secretions is well suited to PCR.

Patient treatment status changes the interpretation of both test types. Antimicrobial therapy reduces bacterial load and can produce false-negative molecular results, but it does not suppress the antibody response. Glucocorticoid therapy, by contrast, can blunt antibody production and lower serologic sensitivity. The clinician should record recent antimicrobial and immunosuppressive drug administration on the laboratory submission form, as this information directly affects result interpretation.

Decision Matrix for Test Selection

Sample Handling and Laboratory Submission

Sample quality determines test validity more than any other controllable factor. For molecular testing, the target is nucleic acid, which degrades rapidly at room temperature. Swabs should be placed in transport medium designed to preserve nucleic acid, and blood for PCR should be collected into EDTA instead of serum tubes. Tissues for PCR should be submitted fresh or frozen, not in formalin, because formalin cross-links nucleic acid and fragments the template. For serology, serum should be separated from the clot promptly to avoid hemolysis, which can interfere with some immunoassay formats.

The laboratory should be consulted before submission when the pathogen is unusual or the matrix is atypical. Commercial identification systems and susceptibility testing methods were developed primarily for human pathogens, and their accuracy with veterinary isolates varies widely depending on the bacterial species and the host animal from which it was isolated Watts and Yancey, commercial identification systems and susceptibility testing of veterinary pathogens. This variation argues for using reference laboratories that maintain veterinary-specific databases and quality control organizms.

Turnaround time differs substantially between test types. Culture and validated antimicrobial susceptibility testing remain slow, and the time required for validated susceptibility methods has not changed despite advances in identification technology Guardabassi et al., diagnostic microbiology in veterinary dermatology. In-clinic laboratories are often not adequately equipped to run up-to-date diagnostic tests, and the quality of susceptibility testing in some laboratory animal diagnostic laboratories has been shown to fall below standards considered acceptable in human diagnostic microbiology Boot, quality assurance program susceptibility testing errors. When rapid results are needed for antimicrobial selection, the clinician should confirm the laboratory's validated rapid protocols instead of assume they exist.

Interpreting Paired and Single Samples

A single serologic titre provides limited information. It cannot distinguish recent infection from past exposure unless a protective threshold has been established for that specific disease and species. Paired acute and convalescent sera collected 2 to 4 weeks apart allow detection of a fourfold or greater rise in titre, which supports active infection. The acute sample should be collected as early as possible in the disease course, and the convalescent sample should be collected after the expected antibody response time. If the first sample was collected late in disease, the titre may already be at its peak and a second sample will not show a rise.

Molecular test results are qualitative or semiquantitative in most veterinary applications. A positive PCR result confirms the presence of pathogen nucleic acid but does not prove that the organizm is viable or that it is the cause of the current clinical signs. Some pathogens are carried asymptomatically, and detection may represent colonisation instead of infection. Cycle threshold values, where reported, provide a rough estimate of nucleic acid load, but they are not standardized across laboratories and should not be used as a precise quantitative measure.

Documentation and Reporting

The laboratory report should include the test method, the sample type and collection date, the result, and the reference range or interpretive criteria used. For serology, the report should state the titre value and the laboratory's threshold for a positive result. For molecular tests, the report should state the target gene or region, the assay format, and whether internal controls were run. The clinician should record the reason for testing, the clinical signs, and the treatment history on the submission form so that the laboratory can flag results that conflict with the clinical picture.

Results that do not match the clinical presentation warrant verification. A negative PCR in a clinically affected animal should prompt consideration of sampling error, inhibitors in the sample, or infection with a strain not covered by the assay. A positive serologic titre in a healthy animal should prompt consideration of vaccination history or past exposure. The MSD Veterinary Manual provides species-specific guidance on interpreting serologic and molecular results for many infectious diseases, and the WOAH terrestrial animal health standards define the confirmatory testing requirements for trade-sensitive diseases.

Species and Production System Considerations

The correct test choice changes with the species and the production system. In companion animal practice, the cost of testing and the speed of results often drive the decision, and point-of-care serologic tests are widely used for screening. In food animal practice, testing is often performed at the herd level instead of the individual level, and the economic threshold for treatment or culling influences the test choice. In herd-level testing, pooled samples can reduce cost but dilute sensitivity, and the pooling strategy must be validated for the specific pathogen and test.

Regulatory requirements also differ by region and by disease. Some diseases are reportable, and the confirmatory testing protocol is defined by national or international standards. The AVMA practice resources provide guidance on reportable disease management in the United States, while the WOAH terrestrial animal health standards apply to international trade. The clinician must know which diseases are reportable in their jurisdiction and which laboratory is authorised to perform confirmatory testing.

Wildlife and exotic species present additional challenges. Reference ranges for serologic tests are often extrapolated from domestic species and may not be valid. Sample volumes are limited, which favours tests that require small amounts of serum or that can be performed on dried blood spots. The Davis-Thompson Foundation pathology resources include case material that illustrates the diagnostic approach in non-domestic species, where the pretest probability of disease and the consequences of a false result differ from those in companion animals.

When to Repeat Testing

Repeat testing is indicated when the initial result does not match the clinical picture, when the disease has a known window period during which tests are negative, or when monitoring response to therapy. For molecular tests, repeat testing after a short interval can confirm a positive result or detect a pathogen that was below the limit of detection. For serology, repeat testing after 2 to 4 weeks is used to document seroconversion. The decision to repeat a test should be based on the specific disease's natural history, not on a general rule, and the clinician should consult species-specific references for the recommended testing interval.

Complications and Failure Modes

Serologic and molecular assays fail in predictable patterns, and early recognition of these patterns prevents misinterpretation. Serologic false negatives arise when sampling occurs before seroconversion, when the host is immunocompromised, or when the assay's antigen panel does not match the circulating strain. False positives occur with cross-reacting antibodies from related pathogens, prior vaccination, or maternal antibody in young animals. Molecular assays fail through nucleic acid degradation during transport, inhibition of the polymerase reaction by blood, feces, or soil components, and contamination of reagents or laboratory surfaces with amplicons from previous runs.

The most consequential failure mode is the uncritical acceptance of a single negative molecular result as proof of absence of infection. Organizms shed intermittently, and sample volume may be inadequate. A negative PCR result from a poorly collected swab carries less information than a positive result from the same sample. Conversely, a positive PCR result does not distinguish viable organizms from residual nucleic acid after successful treatment, a distinction that matters when monitoring therapeutic response.

Detection of early failure requires built-in controls. Molecular assays should include internal amplification controls to identify inhibition, and extraction blanks to identify contamination. Serologic assays require positive and negative control sera on every plate, and paired samples drawn at the correct interval to demonstrate rising or falling titres. Laboratories participating in external proficiency programs identify systematic errors that internal quality control misses. One proficiency program reported major errors in antimicrobial susceptibility testing in nearly 10% of results, and the authors noted that identification capabilities were below acceptable standards in the same laboratories, illustrating that quality problems cluster instead of occur in isolation Boot, DKFZ Quality Assurance Program.

Common Errors and Corrective Actions

Less experienced clinicians frequently submit the wrong sample type for the question asked. A request for serology to document active infection, when paired acute and convalescent samples were never planned, leaves the clinician with a single titre that cannot distinguish recent from past exposure. The corrective action is to decide before sampling whether the question is exposure, active infection, or response to therapy, and to select the assay accordingly.

A second error is overinterpreting a positive molecular result from a site with a resident microbiome. Detection of nucleic acid from a commensal organizm does not establish causation. The corrective action is to correlate the result with cytologic evidence of inflammation and clinical signs, and to use quantitative results where the laboratory provides them.

A third error is ignoring the laboratory's stated validation status. Commercial identification systems vary in accuracy depending on the bacterial species and the host animal from which the isolate was obtained, and veterinary strains are often underrepresented in the databases Watts and Yancey, commercial identification systems. The corrective action is to ask the laboratory whether the assay has been validated for the target species and specimen type, and to interpret results from unvalidated assays with appropriate caution.

Limits of the Evidence

The evidence base for veterinary diagnostic testing is uneven. Some assays have been validated against a gold standard, such as the comparison of selective culture media for Staphylococcus aureus isolation from bovine mastitis using 16S rRNA gene sequencing as the reference method Bautista-Trujillo et al., culture media performance. Other assays, particularly those developed for emerging pathogens or uncommon species, rest on extrapolation from human medicine or from a single laboratory's internal validation.

Expert opinion differs on the clinical weight assigned to molecular typing results. Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry has reduced identification time for key veterinary pathogens and enables high-throughput screening for strain-level differences, as demonstrated for Streptococcus agalactiae from human and animal sources Rothen et al., MALDI-TOF typing. Whether such typing information changes therapeutic decisions in individual cases remains contested, and the clinical relevance of strain-level data must be assessed separately from its technical validity.

Interpretive criteria for antimicrobial susceptibility testing of veterinary pathogens have historically been adapted from human guidelines, and the validity of those adaptations has not been established for all organizm-drug combinations Watts and Yancey, commercial identification systems. Clinicians should recognize that a susceptible result is a prediction based on pharmacokinetic assumptions that may not hold for the species being treated.

Referral, Consultation, and Reporting

Referral to a specialist diagnostic laboratory is warranted when the clinical question exceeds the capacity of the primary laboratory, when results are discordant with clinical findings, or when typing beyond species identification is required for outbreak investigation. Veterinary pathologists and clinical microbiologists can advise on assay selection, sample handling, and interpretation of equivocal results. Educational pathology resources and case material are available through foundations that support diagnostic training Davis-Thompson Foundation.

Regulatory reporting obligations vary by jurisdiction and by pathogen. Reportable diseases, particularly those with trade implications, are governed by international standards that specify diagnostic methods and notification procedures WOAH terrestrial animal health standards. Clinicians should know which diseases are reportable in their region and should contact the relevant authority before or immediately after a presumptive diagnosis, since confirmatory testing may need to be performed at a designated laboratory.

Antimicrobial resistance detected through susceptibility testing carries a separate reporting responsibility. The introduction of prescribing legislation in Germany, requiring culture and susceptibility testing before the use of fluoroquinolones and third-generation cephalosporins in dogs, was followed by a reduction in methicillin-resistant Staphylococcus pseudintermedius isolation in two of three laboratories studied Loeffler et al., antimicrobial prescribing legislation. This observation supports the view that diagnostic testing linked to prescribing policy can influence resistance patterns at a population level, and it underscores the clinician's role in generating surveillance data through routine testing.

Frequently Asked Questions

How Do I Choose Between In-House and Referral Laboratory Testing When Cost Is a Constraint?

In-house testing suits rapid screening and simple pathogen identification, but small in-clinic laboratories are often not adequately equipped to run up-to-date clinical microbiologic diagnostic tests, particularly for antimicrobial susceptibility testing. Referral laboratories using mass spectrometry for identification provide faster and more reliable species-level results than most in-house methods. For molecular assays, consider whether the clinical question requires quantification, genotyping, or resistance gene detection, as these capabilities are rarely available in-house. When budget limits testing, prioritize culture and susceptibility testing for bacterial infections where treatment duration or drug choice is uncertain, and reserve molecular testing for cases where culture has failed or where specific pathogens are difficult to grow.

What Should I Do When the Recommended Sample Type or Transport Medium Is Unavailable?

Use the best available alternative and document the deviation. For bacterial culture, a sterile swab in transport medium is preferable to a dry swab, but a dry swab submitted promptly is still useful for many pathogens. For molecular testing, nucleic acid stabilization buffers preserve DNA and RNA at ambient temperature, but if unavailable, submit samples refrigerated and as soon as possible. Avoid freezing samples destined for virus isolation, as this destroys infectivity, although freezing is acceptable for PCR. Note that some selective media perform differently depending on the pathogen and sample matrix, so interpret results cautiously when the recommended medium was not used. Contact the laboratory before submission if the deviation could compromise the result.

How Does Test Interpretation Change When I Am Working With Exotic or Nontraditional Species?

Interpretation becomes more difficult because validated interpretive criteria are often missing. Antimicrobial susceptibility testing guidelines for veterinary pathogens are largely based on human breakpoints, and the validity of these guidelines for veterinary pathogens has not been established. For species such as reptiles, birds, or wildlife, pharmacokinetic data are sparse, so susceptibility results should be interpreted as microbiologic instead of clinical predictions. Serologic tests validated for one species may cross-react unpredictably in another. Seek species-specific reference intervals from the testing laboratory, and consult the WOAH terrestrial animal health standards for reportable diseases in production and wildlife species.

What Records Should I Keep for Serologic and Molecular Test Results?

Maintain the laboratory accession number, sample type and collection date, test method, and the exact result as reported by the laboratory. Record the clinical indication for testing, any prior results for the same animal, and the interpretation you placed on the result in the medical record. For herd or population testing, retain batch summaries and the laboratory's reference ranges. If you requested additional testing or repeated a sample, document the reason and the outcome. These records support longitudinal interpretation, medicolegal defense, and surveillance reporting. The AVMA practice resources provide general guidance on medical record content and retention expectations in the United States.

How Do I Explain a Discordant Result to a Client or Referring Veterinarian?

Explain that discordant results occur when different tests measure different things. A positive serologic result indicates exposure or vaccination, not necessarily active infection, while a negative PCR result indicates absence of detectable nucleic acid at the time of sampling, not absence of infection. Frame the discrepancy as complementary information instead of error. Describe the possibility of sampling error, timing relative to infection, or assay limitations. Offer a concrete next step, such as repeat testing after an appropriate interval, submission of a different sample type, or referral to a laboratory with more specialised capabilities. Avoid overstating certainty, and acknowledge that some discordance reflects genuine limitations in current diagnostic methods.

When Should I Repeat a Test, and How Long Should I Wait?

Repeat testing is indicated when the result does not match the clinical picture, when the sample was of poor quality, or when the question is about change over time. For serology, paired samples taken 2 to 4 weeks apart distinguish recent infection from past exposure. For molecular tests, repeat sampling after treatment can confirm clearance, but wait until the expected half-life of the organizm or its nucleic acid has passed to avoid false positives from dead organizms. In antimicrobial resistance surveillance, changes in susceptibility testing methods over time can complicate comparison of results between periods, so confirm with the laboratory whether methods have changed before interpreting trends. Consult the MSD Veterinary Manual for species-specific guidance on seroconversion intervals and pathogen shedding duration.

Related Clinical & Scientific Guides

• Hypersensitivity Reactions: Types and Mechanisms
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

References and Further Reading

• Diagnostic microbiology in veterinary dermatology: present and future.. 2017.
• Identification of veterinary pathogens by use of commercial identification systems and new trends in antimicrobial susceptibility testing of veterinary pathogens.. 1994.
• Performance of culture media for the isolation and identification of Staphylococcus aureus from bovine mastitis.. 2013.
• Intervention with impact: Reduced isolation of methicillin-resistant Staphylococcus pseudintermedius from dogs following the introduction of antimicrobial prescribing legislation in Germany.. 2024.
• A simple, rapid typing method for Streptococcus agalactiae based on ribosomal subunit proteins by MALDI-TOF MS.. 2020.
• Frequent major errors in antimicrobial susceptibility testing of bacterial strains distributed under the Deutsches Krebsforschungszentrum Quality Assurance Program.. 2012.
• Davis-Thompson Foundation Veterinary Pathology Resources. Davis-Thompson Foundation.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Immunohistochemistry in Veterinary Diagnostics: Principles and Protocols
• Autoimmunity: Mechanisms and Veterinary Examples
• Diagnostic Cytology: Sample Collection and Interpretation
• Specimen Collection for Microbiology: Swabs, Tissues, and Fluids
• Therapeutic Decision-Making for Autoimmune Disease in Dogs

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.